Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Amgen’s Ustekinumab Biosimilar First to Launch in US

Jan 1, 2025

AIS Health reports that, on 1 January 2025, Amgen launched Wezlana® (ustekinumab), biosimilar to J&J/Janssen’s Stelara® in the US through Optum Health Solution’s private label subsidiary Nuvaila.

Wezlana® was the first interchangeable ustekinumab biosimilar approved by the FDA, in October 2023.  It was launched in Canada in March 2024 and has been approved in Europe (June 2024, as Wezenla™), and approved (January 2024) and PBS-listed (April 2024) in Australia.